A. Bilateral rigidity B. Bradykinesia C. Loud voice D. Postural instability

A. Selecting a once-a-day extended release pill B. Eliminating a medication that is no longer effective C. Spacing out medications so the patient is not taking all of them at once D. Switching to a patch formulation

A. Can help treat motor fluctuations B. Is discouraged in elderly patients C. Can help manage peak-dose dyskinesias D. Can slow disease progression

A. Consider whether or not drug therapy is necessary. B. Monitor other drug therapies when withdrawing a drug that can affect hepatic metabolism. C. Support the implementation of electronic prescribing. D. Eliminate all potentially interacting drugs, even if it requires the addition of multiple alternate options.

A. Switch to the rivastigmine patch B. Switch from carbidopa/levodopa 3 times a day day to rotigotine patch C. Switch to the triple-combination pill carbidopa/levodopa/amantadine D. Switch from ropinirole twice a day to ropinirole once-a-day extended release

A. Adding clozapine B. Adding memantine C. Lower, more frequent carbidopa/levodopa dosing D. Adding a catechol-o-methyltransferase inhibitor

A. Clozapine B. Quetiapine C. Haloperidol D. Rivastigmine

A. Is defined as a drop of 40 mmHg systolic B. Is twice as common in females versus males C. Can be treated with fludrocortisone D. Can be treated with increased levodopa

A. Schizophrenia B. Hallucinations C. Depression D. Fatigue

A. Rotigotine B. Pramipexole C. Selegiline D. Rasagiline